A randomized controlled trial: Effects of compression therapy combined with exercise on chemotherapy-induced peripheral neuropathy in patients with breast cancer

Q3 Medicine

Cancer treatment and research communications Pub Date : 2024-01-01 DOI:10.1016/j.ctarc.2025.100871

Yu Xiaoqian , Hu Jiwei , Zhou Lizhi , Guo Baojia , Guo Luyan , Xu Huiqian , Li Hong , Fan Yijing

{"title":"A randomized controlled trial: Effects of compression therapy combined with exercise on chemotherapy-induced peripheral neuropathy in patients with breast cancer","authors":"Yu Xiaoqian , Hu Jiwei , Zhou Lizhi , Guo Baojia , Guo Luyan , Xu Huiqian , Li Hong , Fan Yijing","doi":"10.1016/j.ctarc.2025.100871","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the effects of compression therapy combined with exercise for cancer patients (EXCAP) in patients with peripheral neuropathy caused by breast cancer chemotherapy.</div></div><div><h3>Methods</h3><div>Overall, 108 patients with peripheral neuropathy after chemotherapy for breast cancer were randomly divided into the control group (routine nursing), experimental group 1 (compression therapy), and experimental group 2 (compression therapy and EXCAP). The National Institute of Cancer Drug Toxicity Rating Scale and the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool were assessed and compared between groups.</div></div><div><h3>Results</h3><div>The incidence of grade 0 peripheral neuropathy in both experimental groups was higher than that in controls (<em>P</em> < 0.001), and the incidence in group 2 was higher than that in group 1 (<em>P</em> < 0.001). The incidence of grade 2 disease in both experimental groups was lower than that in controls (<em>P</em> < 0.001). The rate of symptoms in both experimental groups after the intervention were lower than that in the control group (<em>P</em> < 0.001), and those in experimental group 2 were lower than those in experimental group 1 (<em>P</em> < 0.001). Scores regarding activities of daily living in the experimental groups were lower than those of the control group (<em>P</em> < 0.001), and lower in group 2 than in group 1 (<em>P</em> < 0.001).</div></div><div><h3>Conclusion</h3><div>Compression therapy and EXCAP can effectively reduce the incidence of chemotherapy-induced peripheral neuropathy in patients undergoing breast cancer chemotherapy. They can both positively impact patients' daily lives and symptom experiences; however, they are more effective when combined.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100871"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294225000097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

To investigate the effects of compression therapy combined with exercise for cancer patients (EXCAP) in patients with peripheral neuropathy caused by breast cancer chemotherapy.

Methods

Overall, 108 patients with peripheral neuropathy after chemotherapy for breast cancer were randomly divided into the control group (routine nursing), experimental group 1 (compression therapy), and experimental group 2 (compression therapy and EXCAP). The National Institute of Cancer Drug Toxicity Rating Scale and the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool were assessed and compared between groups.

Results

The incidence of grade 0 peripheral neuropathy in both experimental groups was higher than that in controls (P < 0.001), and the incidence in group 2 was higher than that in group 1 (P < 0.001). The incidence of grade 2 disease in both experimental groups was lower than that in controls (P < 0.001). The rate of symptoms in both experimental groups after the intervention were lower than that in the control group (P < 0.001), and those in experimental group 2 were lower than those in experimental group 1 (P < 0.001). Scores regarding activities of daily living in the experimental groups were lower than those of the control group (P < 0.001), and lower in group 2 than in group 1 (P < 0.001).

Conclusion

Compression therapy and EXCAP can effectively reduce the incidence of chemotherapy-induced peripheral neuropathy in patients undergoing breast cancer chemotherapy. They can both positively impact patients' daily lives and symptom experiences; however, they are more effective when combined.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.